• 

  Sputnik V is more efficient against the Delta variant, says study

  India | June 15, 2021 17:23 IST

  The Sputnik V vaccine was accorded emergency use authorization by the Drugs Controller General of India

• 

  Rs 150 per Covaxin dose to Centre not sustainable in long run: Bharat Biotech

  India | June 15, 2021 15:24 IST

  The supply price of Bharat Biotech''s COVID-19 vaccine Covaxin to the central government at Rs 150 per dose is not sustainable in the long run, the vaccine maker said on Tuesday.

• 

  Rahul Gandhi urges everyone to get vaccinated as soon as possible

  India | June 15, 2021 13:16 IST

  Congress leader Rahul Gandhi on Tuesday urged everyone to follow safety rules and get vaccinated saying no one is safe till the time everyone is.

• 

  AIIMS Delhi to start Covaxin trial for children aged 6-12 from today

  India | June 15, 2021 8:35 IST

  The recruitment for the clinical trial Bharat Biotech's vaccine Covaxin, among children in the age group of 6-12 years will begin at the AIIMS today.

• 

  Delhi AIIMS to begin Covaxin trial on children from Tuesday

  India | June 14, 2021 16:18 IST

  Delhi's All India Institute of Medical Sciences (AIIMS) is expected to begin on Tuesday the recruitment and clinical trials of India's first indigenously developed Covid-19 vaccine, Bharat Biotech's Covaxin, on children.

• 

  Covaxin's phase 3 results soons, says Bharat Biotech

  India | June 13, 2021 9:11 IST

  Bharat Biotech on Saturday said scientific standards and commitment of the indigenously-developed COVID-19 vaccine Covaxin are transparent.

• 

  Covaxin manufacturer Bharat Biotech to carry out clinical trials in US

  India | June 12, 2021 17:30 IST

  In a setback to Bharat Biotech's COVID-19 vaccine Covaxin, the US Food and Drug Administration has "recommended" Ocugen Inc, the US partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data, nixinghopes of Emergency Use Authorisation.

• 

  We respect US's decision: Centre on Covaxin EUA rejection

  India | June 11, 2021 19:18 IST

  Bharat Biotech's application for approval of indigenous COVID-19 vaccine, Covaxin, has been rejected by the US FDA that cited a lack of sufficient data.

• 

  No Emergency Use Authorisation for Bharat Biotech's Covaxin in USA

  India | June 11, 2021 15:51 IST

  Ocugen in a statement on Thursday announced that as recommended by the FDA, it will pursue submission of a biologics licence application (BLA) for Covaxin.

• 

  Covaxin phase 3 full trial data to be made public in July: Bharat Biotech

  India | June 09, 2021 18:48 IST

  Covaxin phase 3 full trial results will be made public in July, Bharat Biotech informed on Wendesday. Covaxin is one of the three vaccines other than Oxford's Covishield and Russia's Sputnik V, that are being administered in India.

• 

  Covaxin protects against Delta, Beta variants of COVID-19, says study

  India | June 09, 2021 13:26 IST

  The Delta variant (B.1.617.2) was first found in India and is the dominant strain in the country, the Beta variant (B.1.351) was first discovered in South Africa.

Advertisement
• 

  Yogi's vaccination push: Special booths for auto rickshaw drivers, street vendors

  India | June 09, 2021 9:05 IST

  The Uttar Pradesh government will organise special vaccination booths for street vendors, auto-rickshaw drivers, e-rickshaw and rickshaw drivers in a bid to encourage them to take the jabs.

• 

  Govt caps vaccine MRP for pvt hospitals: Covishield at Rs 780, Covaxin Rs 1,410

  India | June 08, 2021 21:26 IST

  The Central government on Tuesday also said that it has decided to increase the supply of two made-in-India vaccines - Covishield and Covaxin.

• 

  Day after PM's vaccine push, Centre places order for 44 crore Covaxin and Covishield doses

  India | June 08, 2021 17:50 IST

  Prime Minister Narendra Modi Monday announced a centralised Covid-19 vaccine policy.

• 

  'Each One Pay One': Govt readies new scheme to fund vaccines for poor

  India | June 08, 2021 9:19 IST

  'Each One Pay One' scheme will aim to fund Covid-19 vaccines for the poor.

• 

  Covaxin in Delhi only for those who received it as first dose in 18-44 years age group: HC told

  India | June 07, 2021 16:45 IST

  The Delhi government Monday informed the Delhi High Court that it has directed all government centres, private hospitals and nursing homes here that Covaxin will only be administered to those in the age group of 18-44 years who received it as first dose of anti-COVID vaccine.

• 

  Delhi: AIIMS to start screening children for Covaxin trials from today

  India | June 07, 2021 9:33 IST

  AIIMS in Delhi will begin screening of children aged 2 to 18 years for Covaxin trials from today.

• 

  Covishield produces more antibodies than Covaxin: study

  India | June 07, 2021 12:45 IST

  The study said that both vaccines-- Covishield and Covaxin-- elicited a good response after two doses, but seropositivity rate and median anti-spike antibody were significantly higher in Covishield.

• 

  UP: Special 'pink' Covid vaccination booths for women to begin functioning from today

  India | June 07, 2021 8:28 IST

  Special 'pink booths' will start functioning in Uttar Pradesh from today to encourage women to take Covid vaccine. 

• 

  Covaxin to be given only to second dose beneficiaries in 18-44 category: Delhi to private centres

  India | June 06, 2021 23:17 IST

  The Delhi government on Sunday directed private hospitals and nursing homes to administer Covaxin only to those eligible for the second dose in respect of the 18-44 age group in the month of June or until further orders.